Literature DB >> 19283492

Preformulation study of the inclusion complex irbesartan-beta-cyclodextrin.

Rajashree Hirlekar1, Vilasrao Kadam.   

Abstract

The aim of the present work was to improve the solubility and dissolution profile of irbesartan (IRB), a poorly water-soluble drug by formation of inclusion complex with beta-cyclodextrin (betaCD). Phase solubility studies revealed increase in solubility of the drug upon cyclodextrin addition, showing A(L)-type of graph with slope less than one indicating formation of 1:1 stoichiometry inclusion complex. The stability constant (K(s)) was found to be 104.39 M(-1). IRB-betaCD binary systems were prepared by cogrinding, kneading using alcohol, kneading using aqueous alcohol, and coevaporation methods. Characterization of the binary systems were carried out by differential scanning calorimetry, Fourier transform infrared spectroscopy, scanning electron microscopy, X-ray diffraction, and proton nuclear magnetic resonance. The dissolution profiles of inclusion complexes were determined and compared with those of IRB alone and physical mixture. Among the various methods, coevaporation was the best in which the solubility was increased and dissolution rate of the drug was the highest. The study indicated the usefulness of cyclodextrin technology to overcome the solubility problem of IRB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19283492      PMCID: PMC2663696          DOI: 10.1208/s12249-009-9206-5

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  9 in total

1.  Preformulation study of the inclusion complex warfarin-beta-cyclodextrin.

Authors:  G Zingone; F Rubessa
Journal:  Int J Pharm       Date:  2004-12-28       Impact factor: 5.875

2.  A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug.

Authors:  Garima Chawla; Arvind K Bansal
Journal:  Eur J Pharm Sci       Date:  2007-06-02       Impact factor: 4.384

3.  Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds.

Authors:  Catarina M Fernandes; M Teresa Vieira; Francisco J B Veiga
Journal:  Eur J Pharm Sci       Date:  2002-02       Impact factor: 4.384

4.  NMR Studies of Cyclodextrins and Cyclodextrin Complexes.

Authors:  Hans-Jörg Schneider; Frank Hacket; Volker Rüdiger; Hiroshi Ikeda
Journal:  Chem Rev       Date:  1998-07-30       Impact factor: 60.622

5.  Inclusion complex of trimethoprim with beta-cyclodextrin.

Authors:  Ning Li; Yun-Hui Zhang; Ya-Nan Wu; Xiao-Li Xiong; Ya-Hui Zhang
Journal:  J Pharm Biomed Anal       Date:  2005-09-15       Impact factor: 3.935

6.  Preparation and characterization of inclusion complexes of prazosin hydrochloride with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin.

Authors:  Longxiao Liu; Suyan Zhu
Journal:  J Pharm Biomed Anal       Date:  2005-08-10       Impact factor: 3.935

Review 7.  Clinical overview of irbesartan: a new angiotensin II receptor antagonist.

Authors:  H G Pouleur
Journal:  Am J Hypertens       Date:  1997-12       Impact factor: 2.689

8.  Preparation and study on the solid inclusion complex of cloxacillin sodium with beta-cyclodextrin.

Authors:  Jian-Bin Chao; Bing-Tai Zhang
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2006-11-24       Impact factor: 4.098

Review 9.  The utility of cyclodextrins for enhancing oral bioavailability.

Authors:  Rebecca L Carrier; Lee A Miller; Imran Ahmed
Journal:  J Control Release       Date:  2007-08-16       Impact factor: 9.776

  9 in total
  9 in total

1.  A Self-microemulsifying Drug Delivery System (SMEDDS) for a Novel Medicative Compound Against Depression: a Preparation and Bioavailability Study in Rats.

Authors:  Lan Wu; Yanli Qiao; Lina Wang; Jiahua Guo; Guocheng Wang; Wei He; Lifang Yin; Jinhua Zhao
Journal:  AAPS PharmSciTech       Date:  2015-02-06       Impact factor: 3.246

2.  Formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology.

Authors:  Abdul Ahad; Yousef A Bin Jardan; Mohd Zaheen Hassan; Mohammad Raish; Ajaz Ahmad; Abdullah M Al-Mohizea; Fahad I Al-Jenoobi
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

3.  Formulation and development of a self-nanoemulsifying drug delivery system of irbesartan.

Authors:  Jaydeep Patel; Anjali Patel; Mihir Raval; Navin Sheth
Journal:  J Adv Pharm Technol Res       Date:  2011-01

4.  Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy.

Authors:  Marcin Skotnicki; Barbara Jadach; Agnieszka Skotnicka; Bartłomiej Milanowski; Lidia Tajber; Marek Pyda; Jacek Kujawski
Journal:  Pharmaceutics       Date:  2021-01-18       Impact factor: 6.321

Review 5.  On the Rational Drug Design for Hypertension through NMR Spectroscopy.

Authors:  Eleni Chontzopoulou; Andreas G Tzakos; Thomas Mavromoustakos
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

6.  Preparation of a paeonol-containing temperature-sensitive in situ gel and its preliminary efficacy on allergic rhinitis.

Authors:  Kedan Chu; Lidian Chen; Wei Xu; Huang Li; Yuqin Zhang; Weirong Xie; Jian Zheng
Journal:  Int J Mol Sci       Date:  2013-03-22       Impact factor: 5.923

7.  Hot liquid extrusion assisted drug-cyclodextrin complexation: a novel continuous manufacturing method for solubility and bioavailability enhancement of drugs.

Authors:  Alekhya Sri Nagini Manne; Aswathi R Hegde; Sushil Yadaorao Raut; Rajat Radhakrishna Rao; Vijay Induvadan Kulkarni; Srinivas Mutalik
Journal:  Drug Deliv Transl Res       Date:  2020-09-21       Impact factor: 4.617

8.  Cyclodextrin Complexed Lipid Nanoparticles of Irbesartan for Oral Applications: Design, Development, and In Vitro Characterization.

Authors:  Narendar Dudhipala; Swetha Ettireddy; Ahmed Adel Ali Youssef; Goverdhan Puchchakayala
Journal:  Molecules       Date:  2021-12-13       Impact factor: 4.411

9.  Fabrication of electrospun nanofibres of BCS II drug for enhanced dissolution and permeation across skin.

Authors:  Ravindra N Kamble; Sheetal Gaikwad; Akhil Maske; Sharvil S Patil
Journal:  J Adv Res       Date:  2016-04-04       Impact factor: 10.479

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.